Author

L Wang

Institutions: Mayo Clinic, RIKEN, NSABP Foundation, Indiana University Indianapolis

Observed institutions: Mayo Clinic, Genentech, RIKEN, NSABP Foundation, Indiana University Indianapolis

OpenAlex ID: A5076306973

Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER.

2009 · H Rugo, P Kaufman, et al. · Cancer Research · 9

Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration

2010 · JN Ingle, M Liu, et al. · Cancer Research · 4

Works count: 2

Citation count: 13

H-index: 2

I10-index: